Pharmaceuticals News and Research

RSS

Formatech donates $308K in aseptic liquid fill and finish manufacturing services

Formatech continues its pledge to give back and make a difference in the biotechnology and pharmaceutical community with its Fillanthropy Program. Since the program’s inception, Formatech has donated $308K in aseptic liquid fill and finish manufacturing services to companies developing new drug therapies.

28 Jan 2010

Onset Therapeutics expands its sales force to create nationwide presence

Onset Therapeutics LLC, a specialty pharmaceutical company focused in dermatology, today announced that the Company’s recent growth and future opportunities have facilitated an expansion of its field sales organization to cover more than twenty-five additional major metropolitan areas.

28 Jan 2010

Particle Sciences to share responsibilities in developing anti-HIV microbicides

Particle Sciences, a leading drug development CRO, will share formulation, analytic and production responsibilities in an effort to develop a vaginally administered microbicide, a product specifically designed to prevent the sexual transmission of HIV.

28 Jan 2010

New research findings may lead to new treatment options for abdominal aortic aneurysms

New research findings from a team at the Providence Heart + Lung Institute at St. Paul's Hospital and the University of British Columbia (UBC) may lead to new treatment options for abdominal aortic aneurysms (AAA) - a potentially fatal disease that currently has no pharmacological treatments.

28 Jan 2010

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

GENFIT, a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and neurodegenerative diseases, today announces positive results from a recently completed clinical trial demonstrating the activity of GFT505 on glucose homeostasis. Results from the clinical trial (GFT505-2094) clearly demonstrate the potential of the drug candidate to reduce global cardiovascular risk in prediabetic patients who suffer from impaired fasting plasma glucose, impaired glucose tolerance, and abdominal obesity.

28 Jan 2010

Software tool helps medical service providers respond to serious incidents and disasters affecting children

A statistical study by a specialist group at Childrens Hospital Los Angeles and the University of Southern California indicates that the victims of the January 12 quake include an extraordinarily high number of children- more than 110,000, nearly half of the estimated total.

28 Jan 2010

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Amarin Corporation plc, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, today issued a special letter to its shareholders.

28 Jan 2010

Seroquel XR's FDA approval does not change Decision Resources' earlier antipsychotics market forecast

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the recent decision by the U.S. Food and Drug Administration (FDA) to grant approval of AstraZeneca's Seroquel XR for adjunctive treatment of major depressive disorder will not change Decision Resources' market forecast for the indication. As previously forecasted, Seroquel and Seroquel XR will garner nearly one quarter of antipsychotics sales as adjunctive treatments for major depressive disorder in 2013 in the world's major pharmaceutical markets.

28 Jan 2010

Over 8% of medical devices in circulation are counterfeit: WHO

Counterfeit medical products are becoming an international epidemic. According to the World Health Organization (WHO), more than 8% of the medical devices in circulation are counterfeit. The offending products may be assembled from inferior quality components, or worse yet, from fake parts that could contain toxic materials. In either case the dangers are the same. Counterfeit medical devices pose a significant liability to the manufacturers and a health risk to both the patients and healthcare providers that could result in injury, permanent disability, or even death.

28 Jan 2010

Fuisz Pharma develops novel anti-abuse system for using with abuse prone drugs

Fuisz Pharma today announced the development of a novel anti-abuse system intended for use with abuse prone drugs. This system seeks to address the misuse of addictive drugs with a particular emphasis on opiates and is applicable to all dosage forms.

28 Jan 2010

MedCI forms new strategic alliance with Genta

MedCI LLC, a life-science business consulting services company, announced the formation of a new strategic alliance with Genta Incorporated to secure licensing partners for Genta’s small molecule oncology compound, tesetaxel.

28 Jan 2010

Electrode devices emerge as potential stimulation treatments for depression

Approximately ten to thirty percent of patients with depression do not respond to drug treatments commonly used for the disorder, and this has spurred a search for alternatives. According to Kalorama Information's report "Electrical and Magnetic Neurostimulation," electrode devices that stimulate nerves have emerged as a solution and there is competition among notable device companies to provide the most effective stimulator.

28 Jan 2010

African vaccine maker plans to increase production capacity sevenfold by 2013

Biovac Institute, a South African vaccine maker, said Monday that it is working with other major pharmaceutical firms to increase its annual capacity sevenfold to 35 million doses by 2013, Reuters reports.

28 Jan 2010

Synygy, Health Market Science partner to market commercial analytics solutions for healthcare industry

Synygy Inc., the largest and most experienced provider of sales performance management solutions, and Health Market Science, the leading source of healthcare provider data and advanced analytics, have partnered to market joint sales compensation and commercial analytics solutions for the healthcare industry.

28 Jan 2010

Top pharmaceutical companies select CRi solutions for drug research and development

Gilead Sciences reviewing Notice Letter regarding Teva Pharmaceuticals' generic Viread ANDA

Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Viread® (tenofovir disoproxil fumarate).

27 Jan 2010

Health care stocks gain as reform falters

"Health care stocks lagged the broader market's recovery in 2009," Forbes reports.

27 Jan 2010

WHO addresses handling of H1N1 at Council of Europe meeting

During a Council of Europe meeting on Tuesday to address the WHO's handling of the H1N1 virus, the WHO said it had not "fallen under the sway of drugs firms and exaggerated the dangers of the H1N1 flu virus, but said it might have handled the crisis better," Reuters reports.

27 Jan 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

Positive results from Supernus Pharmaceuticals' SPN 810 Phase IIa trial for ADHD

Supernus Pharmaceuticals Inc., today announced that its Phase IIa U.S. clinical trial for SPN 810 in children with ADHD and persistent serious conduct problems met the primary endpoints of safety and tolerability, as well as showed statistically significant reduction versus baseline in conduct problems across all doses. The trial was initiated in 2009 and was a proof-of-concept, open-label study in children 6 to 12 years of age, assigned to one of four doses over a six-week treatment period, after 2-5 weeks' titration.

27 Jan 2010

Pharmaceuticals News and Research

Formatech donates $308K in aseptic liquid fill and finish manufacturing services

Onset Therapeutics expands its sales force to create nationwide presence

Particle Sciences to share responsibilities in developing anti-HIV microbicides

New research findings may lead to new treatment options for abdominal aortic aneurysms

GENFIT's GFT505 exhibits potential to address unmet needs in prediabetic and diabetic patients

Software tool helps medical service providers respond to serious incidents and disasters affecting children

Amarin reviews 2009 accomplishments; outlines strategy for 2010 and beyond

Seroquel XR's FDA approval does not change Decision Resources' earlier antipsychotics market forecast

Over 8% of medical devices in circulation are counterfeit: WHO

Fuisz Pharma develops novel anti-abuse system for using with abuse prone drugs

MedCI forms new strategic alliance with Genta

Electrode devices emerge as potential stimulation treatments for depression

African vaccine maker plans to increase production capacity sevenfold by 2013

Synygy, Health Market Science partner to market commercial analytics solutions for healthcare industry

Top pharmaceutical companies select CRi solutions for drug research and development

Gilead Sciences reviewing Notice Letter regarding Teva Pharmaceuticals' generic Viread ANDA

Health care stocks gain as reform falters

WHO addresses handling of H1N1 at Council of Europe meeting

Abbott declares quarterly dividend of 40 cents per share

Positive results from Supernus Pharmaceuticals' SPN 810 Phase IIa trial for ADHD

A guide to density measurement excellence eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence